A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2019
Price : $35 *
At a glance
- Drugs RG 7882 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Genentech
- 16 Mar 2019 Results assessing the pharmacokinetics of Dmuc4064a (anti-MUC16 thiomab drug conjugate; three PK analytes-antibody- conjugated MMAE (acMMAE), total antibody (tAb), and unconjugated MMAE)) in patients with platinum-resistant ovarian cancer, were presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 20 Jun 2018 Status changed from active, no longer recruiting to completed.
- 27 Oct 2017 Planned End Date changed from 30 Dec 2017 to 14 Apr 2018.